stockmarketproxy
/
APLSNasdaq SEC EDGAR

Apellis Pharmaceuticals, Inc.

Pharmaceutical Preparations·WALTHAM, MA·FY end 12/31·CIK 1492422
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$1.0B$781.4M$396.6M$75.4M$66.6M
Gross Profit——————
Operating Income$55.4M-$165.0M-$517.1M-$594.6M-$536.3M
Net Income$22.4M-$197.9M-$528.6M-$652.2M-$746.4M
Operating CF$45.3M-$87.9M-$594.7M-$513.7M-$563.1M
Capex$313.0K$403.0K$773.0K$1.5M$1.1M
Free Cash Flow$45.0M-$88.3M-$595.5M-$515.3M-$564.2M
Buybacks——————
Dividends——————
Gross Margin——————
Operating Margin5.5%-21.1%-130.4%-788.4%-805.7%
Net Margin2.2%-25.3%-133.3%-864.7%-1121.3%
FCF Margin4.5%-11.3%-150.2%-683.2%-847.7%
R&D / Revenue29.5%41.9%89.4%513.4%519.6%
Effective Tax7.1%-0.6%-0.4%-0.1%-0.0%
Debt / Equity——0.480.55—
Buybacks / FCF——————

Peer comparison

Pharmaceutical Preparations · 5 peers
CEO Pay Ratio
APLS
2:1
ROIV
518:1
AXSM
23:1
COGT
95:1
PFE
277:1
ABT
166:1
CEO total comp
APLS
—
ROIV
$163M
AXSM
$34M
COGT
$28M
PFE
$28M
ABT
$24M
Net Margin
APLS
2.2%
ROIV
-592.0%
AXSM
-28.7%
COGT
—
PFE
12.4%
ABT
14.7%